Geneva, Switzerland – [May 14, 2026] — ABCDx announced the successful completion of the Eurostars-funded LVOCheck project, a multi-year international program focused on the development of an integrated point-of-care diagnostic platform for rapid identification of large vessel occlusion (LVO) stroke in prehospital settings.
The project was conducted in collaboration with Charité Universitätsmedizin Berlin and FZMB GmbH.
The project, initiated in August 2022 and completed in April 2026, achieved all principal technical and operational milestones across assay development, algorithm development, digital integration, system validation, and clinical activities.
LVOCheck was designed to address a major unmet need in stroke care: the rapid identification of severe ischemic stroke patients eligible for mechanical thrombectomy before hospital arrival. Early and accurate triage remains one of the key bottlenecks limiting timely access to advanced stroke intervention worldwide.
The completed platform integrates:
-a proprietary triplex blood biomarker rapid test,
-smartphone-based quantitative optical readout,
-cloud-connected infrastructure,
-and AI-supported decision algorithms for real-time prehospital assessment.
During the course of the project, ABCDx implemented a strategic redesign of the system architecture, transitioning from a dedicated fluorescence hardware reader toward a scalable smartphone-based solution. This evolution significantly improved deployability, manufacturing scalability, operational robustness, and commercial flexibility for future deployment in ambulance and emergency care environments.
The project also included clinical integration activities with Charité Berlin and the STEMO mobile stroke unit ecosystem, supporting evaluation of the solution within one of Europe’s most advanced prehospital stroke infrastructures.
Jean-Charles Sanchez, CEO and Co-founder of ABCDx, commented: “The successful completion of the LVOCheck project marks an important milestone in the maturation of ABCDx’s diagnostic platform. Beyond the technical achievements, the project enabled the consolidation of key intellectual property, clinical datasets, digital infrastructure, and operational know-how required to support future strategic and commercial opportunities in acute brain injury diagnostics.”
The LVOCheck project further strengthened ABCDx’s position at the intersection of diagnostics, digital health, and AI-enabled emergency medicine. The resulting platform architecture was designed to support future expansion across additional neurological and acute care indications.
The consortium agreement defined ABCDx as coordinator of the project and included collaborative development around assay technologies, digital systems, clinical validation workflows, and exploitation of resulting intellectual property.
The project was funded through the Eurostars programme under the EUREKA framework, with support from participating national funding agencies.
About ABCDx
ABCDx is a Swiss diagnostics company focused on blood-based diagnostic solutions for acute brain injuries, including stroke and traumatic brain injury. The company combines biomarker science, digital diagnostics, and artificial intelligence to develop scalable solutions aimed at improving emergency triage and clinical decision-making.
Media Contact
Tamara Sefcovicova
PR, Marketing and Office Operations Specialist
